Strategic Vision: A Global Pharma Company
Lupin Today
Financial Metrics
Market Cap (3)
US$ 4.0 bn
Revenue (FY22)(4) US$ 2.2 bn
EBITDA (FY22) (4) US$ 311 mn.
FY22 Revenues split
Globally
10th
Largest Generic
company
(by sales¹)
US
6th
Largest Indian
Pharma
(by global sales¹)
Major Markets
3rd
Largest in
the US
(by prescriptions²)
6th
India Pharma
Market Rank²
Netherlands
1
India
38%
ΑΡΙ
6%
Mexico 1
1
North
America
Brazil
36%
1
1
Growth
ROW
2%
EMEA
9%
Markets
9%
India
12
2
◆ Manufacturing
Research
LUPIN
15
7
■20,500+ Global employees
■Products sold in 100 countries
■30 bn+ extended unit capacity
■ API, Generics, Biologics, Specialty, NCE
Mfg
R&D
sites
sites
■ OSD, Injectables, Inhalation,
Ophthalmic, Derm, LARCS
1. LTM sales as of 31st Mar 2022 2. IQVIA MAT Mar-22
3. As of May 18, 2022
4. Exchange rate used US$ 1 = INR 74.24 (Average for FY22)
5View entire presentation